Marraro G
Servizio di Anestesia e Rianimazione, Ospedale Fatebenefratelli e Oftalmico, Milano, Italie.
Cah Anesthesiol. 1994;42(2):159-66.
Artificial surfactant therapy in hyaline membrane disease started in 1980 (Fujiwara). We used it in 10 children with acute respiratory distress syndrome (ARDS) and in 12 newborns suffering from massive aspiration syndrome (MAS). In ARDS, indication was PEEP > or = 8 cmH2O, PaO2 < or = 9 kPa with FiO2 > or = 0.6. Results were rapid. A steady improvement of PaO2 was obtained in 24 hours, generally after a single administration. Three children needed additional doses. In MAS (n = 12) with PaO2 > or = 70 mmHg for FiO2 > 0.6, improvement was obtained very rapidly. Only one newborn received a second dose of surfactant 12 hours after the first one. In MAS as in ARDS all children survived.
1980年开始在透明膜病中应用人工表面活性剂疗法（藤原）。我们将其用于10例急性呼吸窘迫综合征（ARDS）患儿和12例患有大量吸入综合征（MAS）的新生儿。在ARDS中，指征为呼气末正压（PEEP）≥8 cmH₂O，动脉血氧分压（PaO₂）≤9 kPa且吸入氧分数（FiO₂）≥0.6。效果迅速。通常单次给药后24小时内PaO₂就会稳步改善。3例患儿需要追加剂量。在FiO₂>0.6且PaO₂≥70 mmHg的MAS（n = 12）中，改善非常迅速。只有1例新生儿在首次给药12小时后接受了第二剂表面活性剂。在MAS和ARDS中，所有患儿均存活。
